Used in the management of type 2 diabetes mellitus, this compound helps control blood glucose levels by stimulating insulin secretion from pancreatic beta cells. It belongs to the sulfonylurea class, acting primarily by closing ATP-sensitive potassium channels in the beta cells, leading to insulin release. It is particularly suitable for patients with moderate renal impairment due to its hepatic metabolism and biliary excretion, reducing kidney burden. Often prescribed when diet and exercise alone are insufficient, it can be used as monotherapy or in combination with other antidiabetic agents. Its relatively short duration of action lowers the risk of prolonged hypoglycemia compared to longer-acting sulfonylureas.